{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:19:59Z","timestamp":1783574399225,"version":"3.55.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100023674","name":"Deanship of Scientific Research, King Khalid University","doi-asserted-by":"publisher","award":["RGP.02\/304\/46"],"award-info":[{"award-number":["RGP.02\/304\/46"]}],"id":[{"id":"10.13039\/501100023674","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04911-y","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T03:44:09Z","timestamp":1783568649000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-PD-1 single-chain variable fragments in cancer immunotherapy: from molecular engineering to clinical translation"],"prefix":"10.1007","volume":"96","author":[{"given":"Zahraa","family":"AlKhafaje","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6198-8428","authenticated-orcid":false,"given":"H.","family":"Malathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5068-8323","authenticated-orcid":false,"given":"Aniruddh","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7840-4745","authenticated-orcid":false,"given":"J. Precilla","family":"Selvakumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurjant","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3550-6442","authenticated-orcid":false,"given":"Aashna","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6638-2433","authenticated-orcid":false,"given":"Muath","family":"Suliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4600-509X","authenticated-orcid":false,"given":"Aseel","family":"Smerat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"4911_CR1","doi-asserted-by":"publisher","first-page":"113664","DOI":"10.1016\/j.jconrel.2025.113664","volume":"382","author":"J Yang","year":"2025","unstructured":"Yang J, Zhu J, Lu S, Qin H, Zhou W (2025) Transdermal psoriasis treatment inspired by tumor microenvironment-mediated immunomodulation and advanced by exosomal engineering. J Control Release 382:113664","journal-title":"J Control Release"},{"issue":"12","key":"4911_CR2","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1016\/j.ccell.2024.10.017","volume":"42","author":"D Hsiehchen","year":"2024","unstructured":"Hsiehchen D, Elliott A, Xiu J, Seeber A, El-Deiry W, Antonarakis ES et al (2024) Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation. Cancer Cell 42(12):1985\u20131987","journal-title":"Cancer Cell"},{"key":"4911_CR3","doi-asserted-by":"publisher","first-page":"104533","DOI":"10.1016\/j.ebiom.2023.104533","volume":"91","author":"G Gao","year":"2023","unstructured":"Gao G, Shen S, Zhang T, Zhang J, Huang S, Sun Z et al (2023) Lacticaseibacillus rhamnosus Probio-M9 enhanced the antitumor response to anti-PD-1 therapy by modulating intestinal metabolites. EBioMedicine 91:104533","journal-title":"EBioMedicine"},{"key":"4911_CR4","doi-asserted-by":"publisher","first-page":"1751463","DOI":"10.3389\/fimmu.2026.1751463","volume":"17","author":"S Dong","year":"2026","unstructured":"Dong S, Liu Z, Wang Z, Peng X, Huang Q, Yang H et al (2026) Experimental study on synergistic pulses improving the tumor microenvironment and assisting immunotherapy. Front Immunol 17:1751463","journal-title":"Front Immunol"},{"issue":"1","key":"4911_CR5","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1038\/s41467-026-70861-x","volume":"17","author":"F Li","year":"2026","unstructured":"Li F, Han Y, Ou F, Deng L, Li H, Yu X et al (2026) Spatial heterogeneity of MDSCs mediated by ANXA1-FPRs signaling drives immune suppression in OSCC progression. Nat Commun 17(1):2535","journal-title":"Nat Commun"},{"issue":"Pt 3","key":"4911_CR6","doi-asserted-by":"publisher","first-page":"119126","DOI":"10.1016\/j.jep.2024.119126","volume":"338","author":"J Zhou","year":"2025","unstructured":"Zhou J, Guo Z, Peng X, Wu B, Meng Q, Lu X et al (2025) Chrysotoxine regulates ferroptosis and the PI3K\/AKT\/mTOR pathway to prevent cervical cancer. J Ethnopharmacol 338(Pt 3):119126","journal-title":"J Ethnopharmacol"},{"key":"4911_CR7","doi-asserted-by":"publisher","first-page":"114305","DOI":"10.1016\/j.ejca.2024.114305","volume":"211","author":"M Mandal\u00e0","year":"2024","unstructured":"Mandal\u00e0 M, Ferrari A, Brecht IB, Suijkerbuijk KP, Maschke L, Giannarelli D et al (2024) Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study). Eur J Cancer 211:114305","journal-title":"Eur J Cancer"},{"issue":"2","key":"4911_CR8","doi-asserted-by":"publisher","first-page":"100516","DOI":"10.1016\/j.medj.2024.09.005","volume":"6","author":"M Jiang","year":"2025","unstructured":"Jiang M, Sun J, Hu C, Wu L, Fan Y, Wang Z et al (2025) A tumor cornification and immune-infiltration-based scheme for anti-PD-1 plus chemotherapy response in advanced squamous cell lung carcinoma. Med 6(2):100516","journal-title":"Med"},{"key":"4911_CR9","doi-asserted-by":"publisher","first-page":"108399","DOI":"10.1016\/j.pharmthera.2023.108399","volume":"245","author":"SV Retnakumar","year":"2023","unstructured":"Retnakumar SV, Chauvin C, Bayry J (2023) The implication of anti-PD-1 therapy in cancer patients for the vaccination against viral and other infectious diseases. Pharmacol Ther 245:108399","journal-title":"Pharmacol Ther"},{"issue":"11","key":"4911_CR10","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1109\/TBME.2025.3565520","volume":"72","author":"K Qian","year":"2025","unstructured":"Qian K, Yao C, Wang Y, Yang Q, Xiang S, Pei Q et al (2025) Potential of Ultrashort Pulsed Electric Fields to Disrupt Dense Structure in Glioma Tumors. IEEE Trans Biomed Eng 72(11):3233\u20133243","journal-title":"IEEE Trans Biomed Eng"},{"issue":"5","key":"4911_CR11","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.7150\/ijbs.92988","volume":"20","author":"WX Xu","year":"2024","unstructured":"Xu WX, Qu Q, Zhuang HH, Teng XQ, Wei YW, Luo J et al (2024) The Burgeoning Significance of Liquid-Liquid Phase Separation in the Pathogenesis and Therapeutics of Cancers. Int J Biol Sci 20(5):1652\u20131668","journal-title":"Int J Biol Sci"},{"key":"4911_CR12","doi-asserted-by":"publisher","first-page":"1689103","DOI":"10.3389\/fimmu.2025.1689103","volume":"16","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Wang Y, Yin W, Lei Q, Fu Y, Liang Y et al (2025) Identification and validation of prognostic genes and prognostic models associated with cutaneous melanoma and integrative stress response. Front Immunol 16:1689103","journal-title":"Front Immunol"},{"issue":"11","key":"4911_CR13","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S2213-2600(24)00185-1","volume":"12","author":"Y Shiraishi","year":"2024","unstructured":"Shiraishi Y, Nomura S, Sugawara S, Horinouchi H, Yoneshima Y, Hayashi H et al (2024) Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial. Lancet Respir Med 12(11):877\u2013887","journal-title":"Lancet Respir Med"},{"issue":"15","key":"4911_CR14","doi-asserted-by":"publisher","first-page":"e25180","DOI":"10.1097\/MD.0000000000025180","volume":"100","author":"J Chen","year":"2021","unstructured":"Chen J, Wang J, Xu H (2021) Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: A systematic review and network meta-analysis. Med (Baltim) 100(15):e25180","journal-title":"Med (Baltim)"},{"issue":"12","key":"4911_CR15","doi-asserted-by":"publisher","first-page":"10045","DOI":"10.3390\/ijms241210045","volume":"24","author":"MC Stark","year":"2023","unstructured":"Stark MC, Joubert AM, Visagie MH (2023) Molecular Farming of Pembrolizumab and Nivolumab. Int J Mol Sci 24(12):10045","journal-title":"Int J Mol Sci"},{"issue":"Pt 1","key":"4911_CR16","doi-asserted-by":"publisher","first-page":"117488","DOI":"10.1016\/j.bcp.2025.117488","volume":"243","author":"H Yang","year":"2026","unstructured":"Yang H, Chen X, Huang S, Dai H, Xiao Z, Fan J et al (2026) A novel GSH depletor for simultaneous ferroptosis and cuproptosis Activation in hepatocellular carcinoma. Biochem Pharmacol 243(Pt 1):117488","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"4911_CR17","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1021\/acs.bioconjchem.5c00037","volume":"36","author":"Y Zheng","year":"2025","unstructured":"Zheng Y, Cheng H, Jiang S, Tai W (2025) Fc Multisite Conjugation and Prolonged Delivery of the Folate-Targeted Drug Conjugate EC140. Bioconjug Chem 36(4):762\u2013769","journal-title":"Bioconjug Chem"},{"issue":"19","key":"4911_CR18","doi-asserted-by":"publisher","first-page":"e2417920","DOI":"10.1002\/adma.202417920","volume":"37","author":"Y Wang","year":"2025","unstructured":"Wang Y, Dong A, Man J, Chen H, Shen W, Wang L et al (2025) TREM2 scFv-Engineering Escherichia coli Displaying Modulation of Macrophages to Boost Cancer Radio-Immunotherapy. Adv Mater 37(19):e2417920","journal-title":"Adv Mater"},{"issue":"5","key":"4911_CR19","doi-asserted-by":"publisher","first-page":"111090","DOI":"10.1016\/j.humimm.2024.111090","volume":"85","author":"K Heidarnejad","year":"2024","unstructured":"Heidarnejad K, Nooreddin Faraji S, Mahfoozi S, Ghasemi Z, Sadat Dashti F, Asadi M et al (2024) Breast cancer immunotherapy using scFv antibody-based approaches, a systematic review. Hum Immunol 85(5):111090","journal-title":"Hum Immunol"},{"issue":"10","key":"4911_CR20","doi-asserted-by":"publisher","first-page":"101751","DOI":"10.1016\/j.xcrm.2024.101751","volume":"5","author":"K Liu","year":"2024","unstructured":"Liu K, Kong L, Cui H, Zhang L, Xin Q, Zhuang Y et al (2024) Thymosin \u03b11 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy. Cell Rep Med 5(10):101751","journal-title":"Cell Rep Med"},{"issue":"3","key":"4911_CR21","doi-asserted-by":"publisher","first-page":"e006292","DOI":"10.1136\/jitc-2022-006292","volume":"11","author":"KR Michels","year":"2023","unstructured":"Michels KR, Sheih A, Hernandez SA, Brandes AH, Parrilla D, Irwin B et al (2023) Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering. J Immunother Cancer 11(3):e006292","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4911_CR22","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-023-01830-x","volume":"22","author":"J Chen","year":"2023","unstructured":"Chen J, Zhu T, Jiang G, Zeng Q, Li Z, Huang X (2023) Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer. Mol Cancer 22(1):131","journal-title":"Mol Cancer"},{"key":"4911_CR23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.pep.2013.10.023","volume":"94","author":"JJ Drees","year":"2014","unstructured":"Drees JJ, Augustin LB, Mertensotto MJ, Schottel JL, Leonard AS, Saltzman DA (2014) Soluble production of a biologically active single-chain antibody against murine PD-L1 in Escherichia coli. Protein Expr Purif 94:60\u201366","journal-title":"Protein Expr Purif"},{"issue":"1","key":"4911_CR24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12896-022-00752-8","volume":"22","author":"SS Ghaderi","year":"2022","unstructured":"Ghaderi SS, Riazi-Rad F, Qamsari ES, Bagheri S, Rahimi-Jamnani F, Sharifzadeh Z (2022) Development of a human phage display-derived anti-PD-1 scFv antibody: an attractive tool for immune checkpoint therapy. BMC Biotechnol 22(1):22","journal-title":"BMC Biotechnol"},{"issue":"7","key":"4911_CR25","first-page":"1060","volume":"10","author":"E Sasso","year":"2018","unstructured":"Sasso E, D\u2019Avino C, Passariello M, D\u2019Alise AM, Siciliano D, Esposito ML et al (2018) Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies. MAbs 10(7):1060\u20131072","journal-title":"MAbs"},{"issue":"3","key":"4911_CR26","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s10616-019-00316-3","volume":"71","author":"M Kalim","year":"2019","unstructured":"Kalim M, Liang K, Khan MSI, Zhan J (2019) Efficient development and expression of scFv recombinant proteins against PD-L1 surface domain and potency in cancer therapy. Cytotechnology 71(3):705\u2013722","journal-title":"Cytotechnology"},{"key":"4911_CR27","doi-asserted-by":"publisher","first-page":"3415471","DOI":"10.1155\/2020\/3415471","volume":"2020","author":"FL Chang","year":"2020","unstructured":"Chang FL, Tsai KC, Lin TY, Yang TW, Lo YN, Chen WC et al (2020) Astragalus membranaceus-Derived Anti-Programmed Death-1 Monoclonal Antibodies with Immunomodulatory Therapeutic Effects against Tumors. Biomed Res Int 2020:3415471","journal-title":"Biomed Res Int"},{"key":"4911_CR28","doi-asserted-by":"publisher","first-page":"105766","DOI":"10.1016\/j.pep.2020.105766","volume":"177","author":"J Shin","year":"2021","unstructured":"Shin J, Phelan PJ, Gjoerup O, Bachovchin W, Bullock PA (2021) Characterization of a single chain variable fragment of nivolumab that targets PD-1 and blocks PD-L1 binding. Protein Expr Purif 177:105766","journal-title":"Protein Expr Purif"},{"issue":"12","key":"4911_CR29","doi-asserted-by":"publisher","first-page":"e4486","DOI":"10.1002\/pro.4486","volume":"31","author":"F Peissert","year":"2022","unstructured":"Peissert F, Pl\u00fcss L, Giudice AM, Ongaro T, Villa A, Elsayed A et al (2022) Selection of a PD-1 blocking antibody from a novel fully human phage display library. Protein Sci 31(12):e4486","journal-title":"Protein Sci"},{"issue":"8","key":"4911_CR30","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1080\/19420862.2017.1371386","volume":"9","author":"AS Adler","year":"2017","unstructured":"Adler AS, Mizrahi RA, Spindler MJ, Adams MS, Asensio MA, Edgar RC et al (2017) Rare, high-affinity mouse anti-PD-1 antibodies that function in checkpoint blockade, discovered using microfluidics and molecular genomics. MAbs 9(8):1270\u20131281","journal-title":"MAbs"},{"issue":"49","key":"4911_CR31","doi-asserted-by":"publisher","first-page":"12579","DOI":"10.1021\/acs.jpclett.5c03041","volume":"16","author":"K Huang","year":"2025","unstructured":"Huang K, Yang Y, Huang H, Tang Y, Han W, Huang J et al (2025) Machine Learning Accelerates Discovery of High-Performance Corrole Photosensitizers for Optical Imaging Diagnosis and Photodynamic Therapeutics of Nasopharyngeal Carcinoma. J Phys Chem Lett 16(49):12579\u201312588","journal-title":"J Phys Chem Lett"},{"issue":"5","key":"4911_CR32","doi-asserted-by":"publisher","first-page":"101549","DOI":"10.1016\/j.xcrm.2024.101549","volume":"5","author":"I Veith","year":"2024","unstructured":"Veith I, Nurmik M, Mencattini A, Damei I, Lansche C, Brosseau S et al (2024) Assessing personalized responses to anti-PD-1 treatment using patient-derived lung tumor-on-chip. Cell Rep Med 5(5):101549","journal-title":"Cell Rep Med"},{"issue":"10","key":"4911_CR33","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S1470-2045(23)00411-4","volume":"24","author":"X Gao","year":"2023","unstructured":"Gao X, Xu N, Li Z, Shen L, Ji K, Zheng Z et al (2023) Safety and antitumour activity of cadonilimab, an anti-PD-1\/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b\/2 trial. Lancet Oncol 24(10):1134\u20131146","journal-title":"Lancet Oncol"},{"issue":"10","key":"4911_CR34","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1007\/s00262-020-02610-y","volume":"69","author":"LA Vitale","year":"2020","unstructured":"Vitale LA, He LZ, Thomas LJ, Wasiuk A, O\u2019Neill T, Widger J et al (2020) Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy. Cancer Immunol Immunother 69(10):2125\u20132137","journal-title":"Cancer Immunol Immunother"},{"key":"4911_CR35","doi-asserted-by":"publisher","first-page":"42","DOI":"10.4103\/abr.abr_31_22","volume":"12","author":"A Rashti","year":"2023","unstructured":"Rashti A, Akbari V (2023) Construction and Periplasmic Expression of a Bispecific Tandem scFv for Dual Targeting of Immune Checkpoints. Adv Biomed Res 12:42","journal-title":"Adv Biomed Res"},{"issue":"1","key":"4911_CR36","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s13046-022-02474-3","volume":"41","author":"M Passariello","year":"2022","unstructured":"Passariello M, Yoshioka A, Takahashi K, Hashimoto SI, Inoue T, Nakamura K et al (2022) Novel tri-specific tribodies induce strong T cell activation and anti-tumor effects in vitro and in vivo. J Exp Clin Cancer Res 41(1):269","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"4911_CR37","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41420-025-02329-8","volume":"11","author":"M Passariello","year":"2025","unstructured":"Passariello M, Manna L, Rapuano Lembo R, Yoshioka A, Inoue T, Kajiwara K et al (2025) Tri-specific tribodies targeting 5T4, CD3, and immune checkpoint drive stronger functional T-cell responses than combinations of antibody therapeutics. Cell Death Discov 11(1):58","journal-title":"Cell Death Discov"},{"issue":"4","key":"4911_CR38","doi-asserted-by":"publisher","first-page":"e20180391","DOI":"10.1590\/1678-4685-gmb-2018-0391","volume":"42","author":"M Kalim","year":"2020","unstructured":"Kalim M, Wang S, Liang K, Khan MSI, Zhan J (2020) Engineered scPDL1-DM1 drug conjugate with improved in vitro analysis to target PD-L1 positive cancer cells and intracellular trafficking studies in cancer therapy. Genet Mol Biol 42(4):e20180391","journal-title":"Genet Mol Biol"},{"issue":"9","key":"4911_CR39","doi-asserted-by":"publisher","first-page":"e4741","DOI":"10.1002\/pro.4741","volume":"32","author":"T Zhang","year":"2023","unstructured":"Zhang T, Dong S, Zhai Y, Naatz L, Zhou Z, Chen M (2023) Diphtheria toxin-derived, anti-PD-1 immunotoxin, a potent and practical tool to selectively deplete PD-1(+) cells. Protein Sci 32(9):e4741","journal-title":"Protein Sci"},{"key":"4911_CR40","volume-title":"Surface Charge-Determined Protein Coronas of Nanoparticles Control Endothelial Cells Uptake Under Low Magnitude Shear Stress","year":"2026","unstructured":"Zhang H, Zhao S, Zhang Q, Deng C, Zhao C, Wang X et al (eds) (2026) Surface Charge-Determined Protein Coronas of Nanoparticles Control Endothelial Cells Uptake Under Low Magnitude Shear Stress. Wiley Online Library, Exploration"},{"issue":"1","key":"4911_CR41","doi-asserted-by":"publisher","first-page":"016110","DOI":"10.1063\/5.0303756","volume":"10","author":"Q Zhang","year":"2026","unstructured":"Zhang Q, Wang X, Zhang H, He K, Pu D, Chen H et al (2026) Mesenchymal stem cell membrane-coated kaempferol biomimetic nanoformulation for the treatment of atherosclerosis. APL Bioeng 10(1):016110","journal-title":"APL Bioeng"},{"key":"4911_CR42","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.actbio.2022.11.043","volume":"157","author":"Y Xiao","year":"2023","unstructured":"Xiao Y, Zhu T, Zeng Q, Tan Q, Jiang G, Huang X (2023) Functionalized biomimetic nanoparticles combining programmed death-1\/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy. Acta Biomater 157:451\u2013466","journal-title":"Acta Biomater"},{"issue":"31","key":"4911_CR43","doi-asserted-by":"publisher","first-page":"e2400030","DOI":"10.1002\/adhm.202400030","volume":"13","author":"J Tian","year":"2024","unstructured":"Tian J, Wan S, Yang Z, Wang M, Zhou W, Wo G et al (2024) PDL1\/HER2-Targeted Lipid-Encapsulated Oxygen Nanobubbles Combined with Photodynamic Therapy for HER2(+) Breast Cancer Immunotherapy. Adv Healthc Mater 13(31):e2400030","journal-title":"Adv Healthc Mater"},{"issue":"1","key":"4911_CR44","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/s12964-025-02321-w","volume":"23","author":"Y Liu","year":"2025","unstructured":"Liu Y, He W, Li X, Lu X, Wu C, Gao Y et al (2025) Neutrophil membrane-coated circular RNA nanoparticles for targeted immunotherapy in HER2-positive breast cancer brain metastasis. Cell Commun Signal 23(1):333","journal-title":"Cell Commun Signal"},{"issue":"1","key":"4911_CR45","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13045-019-0723-8","volume":"12","author":"Y Yang","year":"2019","unstructured":"Yang Y, Zhang X, Lin F, Xiong M, Fan D, Yuan X et al (2019) Bispecific CD3-HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cells. J Hematol Oncol 12(1):46","journal-title":"J Hematol Oncol"},{"issue":"2","key":"4911_CR46","doi-asserted-by":"publisher","first-page":"200968","DOI":"10.1016\/j.omton.2025.200968","volume":"33","author":"C Riviere","year":"2025","unstructured":"Riviere C, Aljieli M, M\u00e9v\u00e9lec MN, Lantier L, Boursin F, Lajoie L et al (2025) Neospora caninum as delivery vehicle for anti-PD-L1 scFv-Fc: A novel approach for cancer immunotherapy. Mol Ther Oncol 33(2):200968","journal-title":"Mol Ther Oncol"},{"key":"4911_CR47","doi-asserted-by":"publisher","first-page":"1609165","DOI":"10.3389\/fimmu.2025.1609165","volume":"16","author":"Y Lai","year":"2025","unstructured":"Lai Y, Wang F, Cai G, Li Y, Weng J, Cai F et al (2025) Utilization of artificial circular RNAs as miRNA sponges and anti-PD-1 scFv expression platforms to suppress hepatocellular carcinoma progression. Front Immunol 16:1609165","journal-title":"Front Immunol"},{"issue":"5","key":"4911_CR48","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1007\/s10637-018-0689-3","volume":"37","author":"W Hou","year":"2019","unstructured":"Hou W, Yuan Q, Yuan X, Wang Y, Mo W, Wang H et al (2019) A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer. Invest New Drugs 37(5):876\u2013889","journal-title":"Invest New Drugs"},{"key":"4911_CR49","doi-asserted-by":"publisher","first-page":"106196","DOI":"10.1016\/j.pep.2022.106196","volume":"202","author":"J Shin","year":"2023","unstructured":"Shin J, Raissi S, Phelan P, Bullock PA (2023) Rational design of a Nivolumab-based ANTI-PD-1 single chain variable fragment that blocks the interaction between PD-1 expressed on T-CELLS and PD-L1 ON CHO cells. Protein Expr Purif 202:106196","journal-title":"Protein Expr Purif"},{"key":"4911_CR50","doi-asserted-by":"publisher","first-page":"153303382412496","DOI":"10.1177\/15330338241249690","volume":"23","author":"C Chen","year":"2024","unstructured":"Chen C, Chen M, Bai Y, Li Y, Peng J, Yao B et al (2024) A Single-Arm Multi-Center Phase II Clinical Trial of Cadonilimab (anti-PD-1\/CTLA-4) in Combination with or without Conventional Second-Line Treatment for Patients with Extensive Stage Small Cell Lung Cancer. Technol Cancer Res Treat 23:15330338241249690","journal-title":"Technol Cancer Res Treat"},{"key":"4911_CR51","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.bioactmat.2025.09.015","volume":"55","author":"W Yan","year":"2026","unstructured":"Yan W, Li S, Zhang T, Huang J, Deng C, Yuan K et al (2026) Synergistic fusion of CD47, VE-cadherin and mussel adhesion protein promotes endothelialization and suppresses inflammation in vascular stents. Bioactive Mater 55:257\u2013270","journal-title":"Bioactive Mater"},{"issue":"9","key":"4911_CR52","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","volume":"36","author":"S Rafiq","year":"2018","unstructured":"Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ et al (2018) Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol 36(9):847\u2013856","journal-title":"Nat Biotechnol"},{"issue":"10","key":"4911_CR53","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1111\/cas.14169","volume":"110","author":"M Nakajima","year":"2019","unstructured":"Nakajima M, Sakoda Y, Adachi K, Nagano H, Tamada K (2019) Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells. Cancer Sci 110(10):3079\u20133088","journal-title":"Cancer Sci"},{"issue":"8","key":"4911_CR54","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1002\/iub.2280","volume":"72","author":"K Fujiwara","year":"2020","unstructured":"Fujiwara K, Shigematsu K, Tachibana M, Okada N (2020) Development and functional analysis of an anticancer T-cell medicine with immune checkpoint inhibitory ability. IUBMB Life 72(8):1649\u20131658","journal-title":"IUBMB Life"},{"key":"4911_CR55","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40364-020-00198-0","volume":"8","author":"L Qin","year":"2020","unstructured":"Qin L, Zhao R, Chen D, Wei X, Wu Q, Long Y et al (2020) Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth. Biomark Res 8:19","journal-title":"Biomark Res"},{"key":"4911_CR56","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.omto.2020.05.009","volume":"17","author":"CY Yang","year":"2020","unstructured":"Yang CY, Fan MH, Miao CH, Liao YJ, Yuan RH, Liu CL (2020) Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1\/PD-L1 for Treating Pancreatic Cancer. Mol Ther Oncolytics 17:571\u2013585","journal-title":"Mol Ther Oncolytics"},{"key":"4911_CR57","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3389\/fcell.2020.00803","volume":"8","author":"Y Ping","year":"2020","unstructured":"Ping Y, Li F, Nan S, Zhang D, Shi X, Shan J et al (2020) Augmenting the Effectiveness of CAR-T Cells by Enhanced Self-Delivery of PD-1-Neutralizing scFv. Front Cell Dev Biol 8:803","journal-title":"Front Cell Dev Biol"},{"key":"4911_CR58","doi-asserted-by":"publisher","first-page":"8893","DOI":"10.2147\/CMAR.S260915","volume":"12","author":"JT Zhou","year":"2020","unstructured":"Zhou JT, Liu JH, Song TT, Ma B, Amidula N, Bai C (2020) EGLIF-CAR-T Cells Secreting PD-1 Blocking Antibodies Significantly Mediate the Elimination of Gastric Cancer. Cancer Manag Res 12:8893\u20138902","journal-title":"Cancer Manag Res"},{"issue":"1","key":"4911_CR59","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13058-022-01531-1","volume":"24","author":"M Harrasser","year":"2022","unstructured":"Harrasser M, Gohil SH, Lau H, Della Peruta M, Muczynski V, Patel D et al (2022) Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC. Breast Cancer Res 24(1):39","journal-title":"Breast Cancer Res"},{"issue":"4","key":"4911_CR60","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1182\/bloodadvances.2019001110","volume":"5","author":"Z Davis","year":"2021","unstructured":"Davis Z, Felices M, Lenvik T, Badal S, Walker JT, Hinderlie P et al (2021) Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation. Blood Adv 5(4):1069\u20131080","journal-title":"Blood Adv"},{"issue":"10","key":"4911_CR61","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.jcyt.2024.05.012","volume":"26","author":"I Vogiatzi","year":"2024","unstructured":"Vogiatzi I, Lama LM, Lehmann A, Rossignoli F, Gettemans J, Shah K (2024) Allogeneic stem cells engineered to release interferon \u03b2 and scFv-PD1 target glioblastoma and alter the tumor microenvironment. Cytotherapy 26(10):1217\u20131226","journal-title":"Cytotherapy"},{"issue":"6","key":"4911_CR62","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1093\/jnci\/djaf006","volume":"117","author":"N Kanaya","year":"2025","unstructured":"Kanaya N, Seddiq W, Chen KS, Kajiwara Y, Moreno Lama L, Borges P et al (2025) Engineered allogeneic stem cells orchestrate T lymphocyte-driven immunotherapy in immunosuppressive leptomeningeal brain metastasis. J Natl Cancer Inst 117(6):1151\u20131165","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"4911_CR63","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00262-022-03247-9","volume":"72","author":"G Jiang","year":"2023","unstructured":"Jiang G, Ng YY, Tay JCK, Du Z, Xiao L, Wang S et al (2023) Dual CAR-T cells to treat cancers co-expressing NKG2D and PD1 ligands in xenograft models of peritoneal metastasis. Cancer Immunol Immunother 72(1):223\u2013234","journal-title":"Cancer Immunol Immunother"},{"issue":"21\u201322","key":"4911_CR64","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1089\/hum.2022.068","volume":"34","author":"ZS Dunn","year":"2023","unstructured":"Dunn ZS, Qu Y, MacMullan M, Chen X, Cinay G, Wang P (2023) Secretion of 4-1BB Ligand Crosslinked to PD-1 Checkpoint Inhibitor Potentiates Chimeric Antigen Receptor T Cell Solid Tumor Efficacy. Hum Gene Ther 34(21\u201322):1145\u20131161","journal-title":"Hum Gene Ther"},{"issue":"1","key":"4911_CR65","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s12916-023-03016-0","volume":"21","author":"C Yang","year":"2023","unstructured":"Yang C, You J, Pan Q, Tang Y, Cai L, Huang Y et al (2023) Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral Sleeping Beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma. BMC Med 21(1):327","journal-title":"BMC Med"},{"issue":"9","key":"4911_CR66","doi-asserted-by":"publisher","first-page":"4231","DOI":"10.7150\/ijbs.110406","volume":"21","author":"J You","year":"2025","unstructured":"You J, Yang X, Zhao J, Chen H, Tang Y, Ouyang D et al (2025) Enhancing CAR-T Cell Metabolic Fitness and Memory Phenotype for Improved Efficacy against Hepatocellular Carcinoma. Int J Biol Sci 21(9):4231\u20134251","journal-title":"Int J Biol Sci"},{"issue":"33","key":"4911_CR67","doi-asserted-by":"publisher","first-page":"37514","DOI":"10.1021\/acsami.2c10727","volume":"14","author":"J Jie","year":"2022","unstructured":"Jie J, Mao D, Cao J, Feng P, Yang P (2022) Customized Multifunctional Peptide Hydrogel Scaffolds for CAR-T-Cell Rapid Proliferation and Solid Tumor Immunotherapy. ACS Appl Mater Interfaces 14(33):37514\u201337527","journal-title":"ACS Appl Mater Interfaces"},{"key":"4911_CR68","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cancergen.2022.10.003","volume":"268","author":"Y Wang","year":"2022","unstructured":"Wang Y, Fang X, Li M, Ye J, Zhao S, Yu L et al (2022) Mesothelin CAR-T cells secreting PD-L1 blocking scFv for pancreatic cancer treatment. Cancer Genet 268:103\u2013110","journal-title":"Cancer Genet"},{"key":"4911_CR69","doi-asserted-by":"publisher","first-page":"109442","DOI":"10.1016\/j.intimp.2022.109442","volume":"113","author":"P Yuti","year":"2022","unstructured":"Yuti P, Wutti-In Y, Sawasdee N, Kongkhla K, Phanthaphol N, Choomee K et al (2022) Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition. Int Immunopharmacol 113:109442","journal-title":"Int Immunopharmacol"},{"key":"4911_CR70","doi-asserted-by":"publisher","first-page":"115691","DOI":"10.1016\/j.biopha.2023.115691","volume":"168","author":"P Yuti","year":"2023","unstructured":"Yuti P, Sawasdee N, Natungnuy K, Rujirachaivej P, Luangwattananun P, Sujjitjoon J et al (2023) Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma. Biomed Pharmacother 168:115691","journal-title":"Biomed Pharmacother"},{"key":"4911_CR71","doi-asserted-by":"publisher","first-page":"118046","DOI":"10.1016\/j.biopha.2025.118046","volume":"186","author":"Y Li","year":"2025","unstructured":"Li Y, Wang X, Ye F, Hong X, Chen Y, Huang J et al (2025) Acid-responsive engineered bacteria with aberrant In-Situ anti-PD-1 expression for post-ablation immunotherapy of hepatocellular carcinoma. Biomed Pharmacother 186:118046","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"4911_CR72","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1186\/s12967-021-03132-6","volume":"19","author":"Z Yang","year":"2021","unstructured":"Yang Z, Li L, Turkoz A, Chen P, Harari-Steinfeld R, Bobbin M et al (2021) Contextual reprogramming of CAR-T cells for treatment of HER2(+) cancers. J Transl Med 19(1):459","journal-title":"J Transl Med"},{"issue":"16","key":"4911_CR73","doi-asserted-by":"publisher","first-page":"15027","DOI":"10.1007\/s00432-023-05279-9","volume":"149","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Zuo D, Wang K, Lan S, He H, Chen L et al (2023) Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer. J Cancer Res Clin Oncol 149(16):15027\u201315038","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"4911_CR74","doi-asserted-by":"publisher","first-page":"102399","DOI":"10.1016\/j.xcrm.2025.102399","volume":"6","author":"C Guo","year":"2025","unstructured":"Guo C, Gao T, Xue B, Zhang L, Wang S, Xiao R et al (2025) In situ extended immune activation instantly after tumor resection by oncolytic virus controls postoperative tumor recurrence. Cell Rep Med 6(10):102399","journal-title":"Cell Rep Med"},{"issue":"1","key":"4911_CR75","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13046-025-03358-y","volume":"44","author":"S Wang","year":"2025","unstructured":"Wang S, Kong L, Wang L, Zhuang Y, Guo C, Zhang Y et al (2025) Viral expression of NE\/PPE enhances anti-colorectal cancer efficacy of oncolytic adenovirus by promoting TAM M1 polarization to reverse insufficient effector memory\/effector CD8(+) T cell infiltration. J Exp Clin Cancer Res 44(1):97","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"4911_CR76","doi-asserted-by":"publisher","first-page":"e20232104","DOI":"10.1084\/jem.20232104","volume":"221","author":"M Ruggiu","year":"2024","unstructured":"Ruggiu M, Gu\u00e9rin MV, Corre B, Bardou M, Alonso R, Russo E et al (2024) Anti-PD-1 therapy triggers Tfh cell-dependent IL-4 release to boost CD8 T cell responses in tumor-draining lymph nodes. J Exp Med 221(4):e20232104","journal-title":"J Exp Med"},{"issue":"11","key":"4911_CR77","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1093\/neuonc\/noae135","volume":"26","author":"KS Kim","year":"2024","unstructured":"Kim KS, Habashy K, Gould A, Zhao J, Najem H, Amidei C et al (2024) Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood-brain barrier opening: A novel combinatorial immunotherapy regimen for gliomas. Neuro Oncol 26(11):2044\u20132060","journal-title":"Neuro Oncol"},{"issue":"10","key":"4911_CR78","doi-asserted-by":"publisher","first-page":"e1220467","DOI":"10.1080\/2162402X.2016.1220467","volume":"5","author":"P Kleinpeter","year":"2016","unstructured":"Kleinpeter P, Fend L, Thioudellet C, Geist M, Sfrontato N, Koerper V et al (2016) Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death\u2009\u2013\u20091 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition. Oncoimmunology 5(10):e1220467","journal-title":"Oncoimmunology"},{"issue":"23","key":"4911_CR79","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.18632\/oncotarget.26785","volume":"10","author":"LA Mitchell","year":"2019","unstructured":"Mitchell LA, Yagiz K, Hofacre A, Viaud S, Munday AW, Espinoza FL et al (2019) PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models. Oncotarget 10(23):2252\u20132269","journal-title":"Oncotarget"},{"issue":"5","key":"4911_CR80","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1158\/2326-6066.CIR-19-0628","volume":"8","author":"C Lin","year":"2020","unstructured":"Lin C, Ren W, Luo Y, Li S, Chang Y, Li L et al (2020) Intratumoral Delivery of a PD-1-Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade. Cancer Immunol Res 8(5):632\u2013647","journal-title":"Cancer Immunol Res"},{"key":"4911_CR81","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.omtm.2021.01.002","volume":"20","author":"D Br\u00fccher","year":"2021","unstructured":"Br\u00fccher D, Kirchhammer N, Smith SN, Schumacher J, Schumacher N, Kolibius J et al (2021) iMATCH: an integrated modular assembly system for therapeutic combination high-capacity adenovirus gene therapy. Mol Ther Methods Clin Dev 20:572\u2013586","journal-title":"Mol Ther Methods Clin Dev"},{"key":"4911_CR82","doi-asserted-by":"publisher","first-page":"108198","DOI":"10.1016\/j.compbiomed.2024.108198","volume":"171","author":"H Gong","year":"2024","unstructured":"Gong H, Liu Z, Yuan C, Luo Y, Chen Y, Zhang J et al (2024) Identification of cuproptosis-related lncRNAs with the significance in prognosis and immunotherapy of oral squamous cell carcinoma. Comput Biol Med 171:108198","journal-title":"Comput Biol Med"},{"issue":"4","key":"4911_CR83","doi-asserted-by":"publisher","first-page":"e001292","DOI":"10.1136\/jitc-2020-001292","volume":"9","author":"H Khalique","year":"2021","unstructured":"Khalique H, Baugh R, Dyer A, Scott EM, Frost S, Larkin S et al (2021) Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy. J Immunother Cancer 9(4):e001292","journal-title":"J Immunother Cancer"},{"issue":"6","key":"4911_CR84","doi-asserted-by":"publisher","first-page":"e004762","DOI":"10.1136\/jitc-2022-004762","volume":"10","author":"F Ju","year":"2022","unstructured":"Ju F, Luo Y, Lin C, Jia X, Xu Z, Tian R et al (2022) Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade. J Immunother Cancer 10(6):e004762","journal-title":"J Immunother Cancer"},{"key":"4911_CR85","doi-asserted-by":"publisher","first-page":"111579","DOI":"10.1016\/j.intimp.2024.111579","volume":"128","author":"S Mei","year":"2024","unstructured":"Mei S, Peng S, Vong EG, Zhan J (2024) A dual-functional oncolytic adenovirus ZD55-aPD-L1 scFv armed with PD-L1 inhibitor potentiates its antitumor activity. Int Immunopharmacol 128:111579","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"4911_CR86","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1158\/1535-7163.MCT-22-0010","volume":"21","author":"H Wang","year":"2022","unstructured":"Wang H, Khattar V, Hensel JA, Ashton R, Lu Y, Sorace AG et al (2022) Systemic Checkpoint Blockade by PD-L1 Single-Chain Antibody Confers Potent Antitumor Immunity and Long-term Survival. Mol Cancer Ther 21(11):1710\u20131721","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"4911_CR87","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1007\/s12035-024-04406-y","volume":"62","author":"S Maksoud","year":"2025","unstructured":"Maksoud S, Schweiger MW, Tabet EI, Xiao T, Hokayem JE, Zinter M et al (2025) Arming AAV9 with a Single-Chain Fragment Variable Antibody Against PD-1 for Systemic Glioblastoma Therapy. Mol Neurobiol 62(2):2617\u20132625","journal-title":"Mol Neurobiol"},{"issue":"5","key":"4911_CR88","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.62347\/LJNC8404","volume":"14","author":"Y Yang","year":"2024","unstructured":"Yang Y, Huang Q, Cheng M, Deng L, Liu X, Zheng X et al (2024) Efficacy and advantage of immunotherapy for melanoma via intramuscular co-expression of plasmid-encoded PD-1 and CTLA-4 scFvs. Am J Cancer Res 14(5):2626\u20132642","journal-title":"Am J Cancer Res"},{"issue":"5","key":"4911_CR89","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1097\/HEP.0000000000000320","volume":"78","author":"Q Wu","year":"2023","unstructured":"Wu Q, Pan C, Zhou Y, Wang S, Xie L, Zhou W et al (2023) Targeting neuropilin-1 abolishes anti-PD-1-upregulated regulatory T cells and synergizes with 4-1BB agonist for liver cancer treatment. Hepatology 78(5):1402\u20131417","journal-title":"Hepatology"},{"issue":"763","key":"4911_CR90","doi-asserted-by":"publisher","first-page":"eadl3598","DOI":"10.1126\/scitranslmed.adl3598","volume":"16","author":"Z Chen","year":"2024","unstructured":"Chen Z, Ji W, Feng W, Cui J, Wang Y, Li F et al (2024) PTPRT loss enhances anti-PD-1 therapy efficacy by regulation of STING pathway in non-small cell lung cancer. Sci Transl Med 16(763):eadl3598","journal-title":"Sci Transl Med"},{"issue":"17","key":"4911_CR91","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2024947","volume":"384","author":"GK Friedman","year":"2021","unstructured":"Friedman GK, Johnston JM, Bag AK, Bernstock JD, Li R, Aban I et al (2021) Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas. N Engl J Med 384(17):1613\u20131622","journal-title":"N Engl J Med"},{"issue":"3","key":"4911_CR92","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3233\/HAB-180333","volume":"26","author":"A Mesgari-Shadi","year":"2018","unstructured":"Mesgari-Shadi A, Sarrafzadeh M-H, Barar J, Omidi Y (2018) Cost-effective batch production process of scFv antibody in Escherichia coli. Hum Antib 26(3):149\u2013157","journal-title":"Hum Antib"},{"key":"4911_CR93","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ces.2015.10.029","volume":"141","author":"S Klutz","year":"2016","unstructured":"Klutz S, Holtmann L, Lobedann M, Schembecker G (2016) Cost evaluation of antibody production processes in different operation modes. Chem Eng Sci 141:63\u201374","journal-title":"Chem Eng Sci"},{"key":"4911_CR94","doi-asserted-by":"publisher","first-page":"1729468","DOI":"10.3389\/fimmu.2025.1729468","volume":"16","author":"NO Porozova","year":"2025","unstructured":"Porozova NO, Petukhova NV, Gureev MA, Moiseev IS, Eliseev IE, Fedorova LV et al (2025) Beyond monoclonal antibodies: constraints and the case for alternative PD-1\/PD-L1-targeting formats. Front Immunol 16:1729468","journal-title":"Front Immunol"},{"issue":"1","key":"4911_CR95","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1186\/s12967-025-07183-x","volume":"23","author":"P Safarzadeh Kozani","year":"2025","unstructured":"Safarzadeh Kozani P, Safarzadeh Kozani P (2025) Preventing secondary primary malignancies (SPMs) in CAR-T cell therapy through site-specific transgene integration into genomic safe harbors (GSHs). J Transl Med 23(1):1155","journal-title":"J Transl Med"},{"key":"4911_CR96","doi-asserted-by":"publisher","first-page":"e944927","DOI":"10.12659\/MSM.944927","volume":"30","author":"DV Parums","year":"2024","unstructured":"Parums DV, Editorial (2024) First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) - Lifileucel (Amtagvi). Med Sci Monit 30:e944927","journal-title":"Med Sci Monit"},{"key":"4911_CR97","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13036-019-0189-9","volume":"13","author":"L He","year":"2019","unstructured":"He L, Yang H, Tang J, Liu Z, Chen Y, Lu B et al (2019) Intestinal probiotics E. coli Nissle 1917 as a targeted vehicle for delivery of p53 and Tum-5 to solid tumors for cancer therapy. J Biol Eng 13:58","journal-title":"J Biol Eng"},{"issue":"11","key":"4911_CR98","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1136\/gutjnl-2023-330291","volume":"72","author":"X Kang","year":"2023","unstructured":"Kang X, Liu C, Ding Y, Ni Y, Ji F, Lau HCH et al (2023) Roseburia intestinalis generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8(+) T cells. Gut 72(11):2112\u20132122","journal-title":"Gut"},{"issue":"6","key":"4911_CR99","doi-asserted-by":"publisher","first-page":"e006822","DOI":"10.1136\/jitc-2023-007068","volume":"11","author":"W Shen","year":"2023","unstructured":"Shen W, Shi P, Dong Q, Zhou X, Chen C, Sui X et al (2023) Discovery of a novel dual-targeting D-peptide to block CD24\/Siglec-10 and PD-1\/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy. J Immunother Cancer 11(6):e006822","journal-title":"J Immunother Cancer"},{"issue":"7","key":"4911_CR100","doi-asserted-by":"publisher","first-page":"e008811","DOI":"10.1136\/jitc-2024-008811","volume":"12","author":"Y Chen","year":"2024","unstructured":"Chen Y, Zhou Y, Ren R, Chen Y, Lei J, Li Y (2024) Harnessing lipid metabolism modulation for improved immunotherapy outcomes in lung adenocarcinoma. J Immunother Cancer 12(7):e008811","journal-title":"J Immunother Cancer"},{"issue":"16suppl","key":"4911_CR101","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1200\/JCO.2024.42.16_suppl.2548","volume":"42","author":"H Qin","year":"2024","unstructured":"Qin H, Wang Y, Yi Y, Gao F, Zou D, Li Y et al (2024) Phase 1 study of GT101 as an autologous tumor infiltrating lymphocyte (TIL) therapy in advanced solid tumors. J Clin Oncol 42(16suppl):2548","journal-title":"J Clin Oncol"},{"issue":"16suppl","key":"4911_CR102","doi-asserted-by":"publisher","first-page":"5533","DOI":"10.1200\/JCO.2025.43.16_suppl.5533","volume":"43","author":"H Qin","year":"2025","unstructured":"Qin H, Wang Y, Yi Y, Gao F, Zou D, Li Y et al (2025) GT101 autologous TIL therapy in patients with recurrent and metastatic cervical cancer: A phase 1 study. J Clin Oncol 43(16suppl):5533","journal-title":"J Clin Oncol"},{"issue":"Suppl 7","key":"4911_CR103","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1158\/1538-7445.AM2023-4049","volume":"83","author":"LA Pikor","year":"2023","unstructured":"Pikor LA, Bernard A, Brassard N, Fritzsche A, Kluew A, Jilesen ZK et al (2023) TIDAL-01: A selected TIL process that enriches for neoantigen reactive TIL in solid tumors. Cancer Res 83(Suppl 7):4049","journal-title":"Cancer Res"},{"key":"4911_CR104","doi-asserted-by":"publisher","first-page":"1178382","DOI":"10.3389\/fmolb.2023.1178382","volume":"10","author":"E Robilotti","year":"2023","unstructured":"Robilotti E, Zeitouni N, Orloff M (2023) Biosafety and biohazard considerations of HSV-1\u2013based oncolytic viral immunotherapy. Front Mol Bios 10:1178382","journal-title":"Front Mol Bios"},{"issue":"12","key":"4911_CR105","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/jvh.13886","volume":"30","author":"Q Ning","year":"2023","unstructured":"Ning Q, Yang T, Guo X, Huang Y, Gao Y, Liu M et al (2023) CHB patients with rtA181T-mutated HBV infection are associated with higher risk hepatocellular carcinoma due to increases in mutation rates of tumour suppressor genes. J Viral Hepat 30(12):951\u2013958","journal-title":"J Viral Hepat"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04911-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04911-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04911-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:02:35Z","timestamp":1783573355000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04911-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":105,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4911"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04911-y","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"21 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ChatGPT5 was used for language editing, grammatical checks, and text refinement. Authors approved all sections of the article and accept the correspondence of all contents.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"AI declaration"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not Applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not Applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trials number"}}],"article-number":"73"}}